PROTAC HK2 Degrader-1 (50 mg/kg, Intraperitoneal injection, bid, for nine times, into six-weekold female BALB/c mice) inhibits tumor growth in 4T1 tumor models[1].
PROTAC HK2 Degrader-1 (50 mg/kg, Intraperitoneal injection, bid, for nine times, six-weekold female BALB/c mice) can induce GSDME-dependent pyroptosis to realize tumor immune response and effectively inhibit breast tumor growth[1].
PROTAC HK2 Degrader-1 (Cisplatin (HY-17394) 10mg/kg, i.v., C-02 50mg/kg, i.p., 25 days, into six-weekold female BALB/c mice) can sensitize Cisplatin (HY-17394) while reducing the colon side effects of Cisplatin (HY-17394), which has potential clinical value[1].
| Animal Model: | xenograft models , into six-weekold female BALB/c mice[1] |
| Dosage: | 50 mg/kg |
| Administration: | Intraperitoneal injection, bid, for nine times. |
| Result: | Reduced proliferation and damaged nuclei in mouse models.
Increased the levels of Cytokines IL-1β, IFN-γ, and TNF-α significantly and decreased the level of TGF-β and IL-10.
Elevated levels of cleaved-Casp-3 and GSDME-N in tumor tissues of mouse.
|
| Animal Model: | breast tumor model in mice by injecting 4T1 cells subcutaneously into six-weekold female BALB/c mice[1] |
| Dosage: | Cisplatin (HY-17394) 10mg/kg, 50mg/kg |
| Administration: | Cisplatin (HY-17394) (10mg/kg, i.v.), 50mg/kg, i.p., 25 days |
| Result: | Inhibited tumor growth and tumor volume.
Decreased HK2 protein level, while co- treated with Cisplatin (HY-17394).
Could alleviate Cisplatin (HY-17394) aggravated colon damage.
|
